Jazzy Franchise23.jpg Official

: By mid-2023, the company achieved a major milestone: 66% of total revenues came from its newer "growth drivers"— Xywav , Epidiolex , and Rylaze .

: A major shift occurred toward on-demand services , with customers demanding seamless mobile booking for everything from home repairs to wellness. The Bottom Line

Whether you were tracking ticker symbols or box scores, 2023 was a defining year for the "Jazz" brand. From the pharmaceutical labs in Dublin to the hardwood in Salt Lake City, both franchises faced critical transitions that set the stage for their 2024 and 2025 goals. 1. Jazz Pharmaceuticals: A Year of Blockbuster Growth Jazzy franchise23.jpg

While the pharmaceutical side was hitting record highs, the basketball franchise was navigating a "Journey of Pain"—a strategic rebuild aimed at long-term contention.

: The sector added nearly 15,000 units and created roughly 254,000 jobs , despite economic uncertainty. : By mid-2023, the company achieved a major

: This strategic retreat allowed them to pick up Taylor Hendricks at ninth overall in the 2023 draft, a foundational piece for their current roster. 3. Broader 2023 Franchise Trends

: The oncology portfolio was on a tear, with Rylaze sales jumping 43% year-over-year by Q3. 2. The Utah Jazz: The "Quiet" Rebuild From the pharmaceutical labs in Dublin to the

For investors, "Jazzy 23" was synonymous with commercial execution. spent the year proving it could grow past its traditional reliance on older sleep medications.